1. Home
  2. BRIA vs IMAB Comparison

BRIA vs IMAB Comparison

Compare BRIA & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BRIA
  • IMAB
  • Stock Information
  • Founded
  • BRIA 2011
  • IMAB 2014
  • Country
  • BRIA Singapore
  • IMAB United States
  • Employees
  • BRIA N/A
  • IMAB N/A
  • Industry
  • BRIA
  • IMAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • BRIA
  • IMAB Health Care
  • Exchange
  • BRIA NYSE
  • IMAB Nasdaq
  • Market Cap
  • BRIA 86.3M
  • IMAB 87.2M
  • IPO Year
  • BRIA 2024
  • IMAB 2020
  • Fundamental
  • Price
  • BRIA $2.99
  • IMAB $0.99
  • Analyst Decision
  • BRIA
  • IMAB Strong Buy
  • Analyst Count
  • BRIA 0
  • IMAB 3
  • Target Price
  • BRIA N/A
  • IMAB $8.00
  • AVG Volume (30 Days)
  • BRIA 28.9K
  • IMAB 270.7K
  • Earning Date
  • BRIA 02-19-2025
  • IMAB 03-13-2025
  • Dividend Yield
  • BRIA N/A
  • IMAB N/A
  • EPS Growth
  • BRIA N/A
  • IMAB N/A
  • EPS
  • BRIA 92.24
  • IMAB N/A
  • Revenue
  • BRIA $55,755,669.00
  • IMAB $3,313,984.00
  • Revenue This Year
  • BRIA N/A
  • IMAB N/A
  • Revenue Next Year
  • BRIA N/A
  • IMAB N/A
  • P/E Ratio
  • BRIA $0.03
  • IMAB N/A
  • Revenue Growth
  • BRIA 8.03
  • IMAB N/A
  • 52 Week Low
  • BRIA $3.16
  • IMAB $0.84
  • 52 Week High
  • BRIA $4.38
  • IMAB $2.00
  • Technical
  • Relative Strength Index (RSI)
  • BRIA N/A
  • IMAB 43.19
  • Support Level
  • BRIA N/A
  • IMAB $1.03
  • Resistance Level
  • BRIA N/A
  • IMAB $1.10
  • Average True Range (ATR)
  • BRIA 0.00
  • IMAB 0.06
  • MACD
  • BRIA 0.00
  • IMAB -0.01
  • Stochastic Oscillator
  • BRIA 0.00
  • IMAB 7.58

About BRIA BRILLIA INC

BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.

About IMAB I-MAB

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

Share on Social Networks: